India Biopharmaceutical Market Size, Share & Forecast, By Product Type, Therapy Area & End User, 2026-2031

The India Biopharmaceutical Market was valued at USD 42 billion in 2025 under the report scope, which includes therapeutic biologics and vaccines manufactured or commercialized by India-based entities for domestic and export markets. Vaccines contributed about USD 18 billion, while biotherapeutics contributed about USD 24 billion. The estimate excludes standalone diagnostics, medical devices, small-molecule drugs and pure research services, preventing scope inflation and double counting.

The market is projected to reach USD 80 billion by 2031, expanding at an 11.34% CAGR from the 2025 base. The forecast assumes treatment-equivalent volume growth of roughly 7% to 9% annually, supplemented by a richer product mix, regulated-market biosimilar launches and advanced vaccine platforms. Growth is expected to remain above the broader pharmaceutical industry because biologics penetration is rising from a lower base and policy support is targeting domestic manufacturing and clinical infrastructure.

The largest profit-pool shift will be from high-volume vaccine and first-generation recombinant products toward complex biosimilars, monoclonal antibodies, long-acting proteins and selected advanced therapies. Vaccines will remain strategically important, but their share is modeled to decline as therapeutic biologics scale faster. Higher-value products offer better revenue per batch, but require greater analytical, clinical, device and pharmacovigilance capability. Commercial success will therefore depend on integrated development and market access rather than manufacturing capacity alone.

The largest execution risk is the combination of capital intensity and regulatory uncertainty. Biologic facilities require specialized process equipment, aseptic operations, analytical laboratories and long validation cycles before commercial revenue is secured. A delay in clinical data, regulatory review or inspection clearance can leave expensive capacity underutilized. Imported single-use assemblies, chromatography resins and critical consumables add supply-chain exposure, while biosimilar price competition can compress returns soon after launch.

India is the second-largest market among the selected Asian peer set, behind China but ahead of South Korea, Singapore and Malaysia in estimated 2025 value. Its modeled 11.34% CAGR is faster than China and South Korea, supported by vaccine scale, a large biosimilar base and lower manufacturing costs. However, India trails the strongest peers in R&D intensity, original biologics and globally differentiated intellectual property, which limits value capture despite strong production capability.

Domestic demand will be driven by oncology, diabetes, autoimmune disease, preventive vaccination and improved hospital access to specialty medicines. Noncommunicable diseases account for roughly three-quarters of deaths in India, supporting a long-duration treatment pool for biologics. Biosimilars can widen access by lowering treatment cost relative to originator products, while public procurement remains important for vaccines. Adoption will still depend on physician confidence, reimbursement, cold-chain availability and patient-support programs.

The competitive landscape is led by Serum Institute of India, Biocon Biologics, Bharat Biotech, Biological E, Zydus Lifesciences, Intas Pharmaceuticals, Dr. Reddy's Laboratories, Indian Immunologicals, Reliance Life Sciences and Gennova Biopharmaceuticals. Their strengths differ across vaccines, biosimilars, insulin, oncology biologics, recombinant proteins and advanced platforms. Market shares are not disclosed consistently because several firms are private and group reporting does not isolate India-specific biopharma revenue.